Elevated plasma phospholipase A₂ and platelet-activating factor acetylhydrolase activity in colorectal cancer

Abstract

This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A₂) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.